Moderna Inc (NASDAQ:MRNA) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.MRNA stock is struggling to find support. Check out the latest moves here.What To Know: The decline continues despite Moderna’s announcement on Monday that it dosed the first patient in a Phase 1/2 study for mRNA-2808, its investigational T-cell engager for multiple myeloma.This positive step was tempered by the fallout from the company’s Oct. 23 update, when it announ ...